MedTrace Logo

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

NCT02806128 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-01-06

No results posted yet for this study

Summary

Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction.

Conditions

  • Cerebral Infarction

Interventions

DRUG

Human Urinary Kallidinogenase for Injection

Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time

Sponsors & Collaborators

  • Huisheng Chen

    lead OTHER

Principal Investigators

  • Huisheng Chen · General Hospital of Shenyang Military Region

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806128 on ClinicalTrials.gov